Objective Stakes: Availability of adequate test model systems is essential to the development of risk assessment programmes for nuclear receptors-interacting compounds (NR-ICs) (drugs, industrial compounds, cosmetics, environmental contaminants and food components). Goal: The objective of the EXERA project is to develop novel 3D in vitro models of mouse tissues from five major organs for the pharmaco-toxicological analysis of Estrogen Receptors-Interacting Compounds (ER-ICs): liver, skin and bone (non reproductive systems), ovary and testis (male and female reproductive systems). Work content: This objective will be pursued through a Work Programme which allies an integrated scientific approach between innovative technologies such as the 3D-culture device, known as "Rotary Cell Culture System" (RCCS Technology adapted to the needs of this project), established transgenic mouse lines (estrogen-reporter mice, here called MOUSE-1) and genomic platforms for ER-ICs characterization. Our strategy is planned around 5 main points including, besides the mentioned technologies, multiple cell cultures quality controls, immortalisation control, cell banking and the use of specific markers of estrogenic action and cell differentiation/health, in order to obtain estrogen-responsive 3D-cultures of well differentiated mouse cells. Expected Results and Related Benefits: The corresponding work programme will be ensured by an important involvement of the whole partnership and by a high degree of coordination between 7 private and 3 public institutions. The expected results of our effort will be scientifically, socially and economically relevant: 1) application/adaptation of new 3D-culture technologies to cell cultures devoted to the study of ER-ICs; 2) constitution of a cell bank and, finally 3) a battery of differentiated 3D cell-based systems derived from estrogen-reporter mice for basic and applied research (e.g. pharmacology and toxicology), public use and industrial use. Fields of science medical and health sciencesbasic medicinetoxicologymedical and health sciencesbasic medicinepharmacology and pharmacy Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2005-1.2.3-4 - Development of new in vitro tests to replace animal experimentation Call for proposal FP6-2005-LIFESCIHEALTH-7 See other projects for this call Funding Scheme STREP - Specific Targeted Research Project Coordinator AZIENDA OSPEDALIERA- SPEDALI CIVILI DI BRESCIA EU contribution No data Address P.le Spedali Civili di Brescia BRESCIA Italy See on map Links Website Opens in new window Total cost No data Participants (8) Sort alphabetically Sort by EU Contribution Expand all Collapse all UNIVERSITY OF TURKU Finland EU contribution No data Address Itainen Pitkakatu, 4A TURKU See on map Links Website Opens in new window Total cost No data ATHLONE INSTITUTE OF TECHNOLOGY Ireland EU contribution No data Address Dublin Road ATHLONE See on map Links Website Opens in new window Total cost No data CELLON SA Luxembourg EU contribution No data Address 29 Am Becheler BERELDANGE See on map Links Website Opens in new window Total cost No data HORMOS MEDICAL OY Finland EU contribution No data Address Itainen Pitkatu 4 B TURKU See on map Links Website Opens in new window Total cost No data DNAVISION Belgium EU contribution No data Address rue Adrienne Bolland 8 GOSSELIES See on map Links Website Opens in new window Total cost No data BIOUETIKON LIMITED Ireland EU contribution No data Address R&D Building, Dublin City University, Glasnevin DUBLIN 9 See on map Links Website Opens in new window Total cost No data ALTA SRL Italy EU contribution No data Address Via Fiorentina 1 SIENA See on map Links Website Opens in new window Total cost No data UNIVERSITA DEGLI STUDI DI MILANO Italy EU contribution No data Address Via Festa del Perdono, 7 MILAN See on map Links Website Opens in new window Total cost No data